Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Clindamycin Phosphate Topical Solution (02483769). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

CLINDAMYCIN

All products: not a benefit

Other products in the same Health Canada class (D10AF) — coverage varies; not interchangeable

  • Benzoyl peroxide + clindamycin (Clindoxyl): general benefit
  • Adapalene + benzoyl peroxide + clindamycin (Cabtreo): limited Use 724

Taro-Clindamycin · DIN 02266938 · 1% · Top Sol

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Clindamycin · DIN 02266938 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2017-03-28 Health Canada: Marketed since 2005-10-03 · brand TARO-CLINDAMYCIN · ATC D10AF01 CLINDAMYCIN · form Solution · route Topical · ingredients CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 1 %/W/V · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75233 · Verify on the e-Formulary ↗ (DIN 02266938)

Source record
DIN 02266938: Taro-Clindamycin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840404017; group id 809; item number 1987; lccId None; manufacturer id TAR Source form: Top Sol; strength: 1% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.5072; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02266938 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75233
Interchangeable products
Dalacin T 1% · DIN 00582301 · not recorded
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02266938
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Dalacin T 1% · DIN 00582301 · 1% · Top Sol

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-12-17 — choose a marketed DIN from the same-category list.Discontinued 2021-12-17 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-12-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-12-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dalacin T 1% · DIN 00582301 Manufacturer: Pfizer Canada Inc.; listing date 2017-03-28 Health Canada: Cancelled post market since 2021-12-17 · brand DALACIN T 1% · ATC D10AF01 CLINDAMYCIN · form Solution · route Topical · ingredients CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 1 %/W/V · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Dalacin T 1%: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11260 · Verify on the e-Formulary ↗ (DIN 00582301)

Source record
DIN 00582301: Dalacin T 1% Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840404017; group id 809; item number 1987; lccId None; manufacturer id PFI Source form: Top Sol; strength: 1% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00582301 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11260
Interchangeable products
Taro-Clindamycin · DIN 02266938 · not recorded
Shortage status: active shortage (reported 2018-01-26, last updated 2019-03-11) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00582301
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-12-17 — choose a marketed DIN from the same-category list.

CLINDAMYCIN HCL

18 general benefit · 2 not a benefit

Other products in the same Health Canada class (D10AF) — coverage varies; not interchangeable

  • Benzoyl peroxide + clindamycin (Clindoxyl): general benefit
  • Adapalene + benzoyl peroxide + clindamycin (Cabtreo): limited Use 724

Auro-Clindamycin · DIN 02436906 · 150mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Clindamycin · DIN 02436906 Manufacturer: Auro Pharma Inc.; listing date 2015-05-28 Daily cost (source): $1.7736 Health Canada: Marketed since 2015-03-02 · brand AURO-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 150 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Clindamycin: Formulary list price $0.2217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92122 · Verify on the e-Formulary ↗ (DIN 02436906)

Source record
DIN 02436906: Auro-Clindamycin Raw flags: sec3=Y Item: 081228006; group id 44; item number 0100; lccId None; manufacturer id AUR Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.2217; ministry $0.2217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02436906 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92122
Interchangeable products
Apo-Clindamycin · DIN 02245232 · $0.2217 Clindamycin · DIN 02400529 · $0.2217 Dalacin C · DIN 00030570 · not recorded Jamp-Clindamycin · DIN 02483734 · $0.2217 M-Clindamycin · DIN 02479923 · $0.2217 Med-Clindamycin · DIN 02462656 · $0.2217 NRA-Clindamycin · DIN 02493748 · $0.2217 Riva-Clindamycin · DIN 02468476 · $0.2217 Teva-Clindamycin · DIN 02241709 · $0.2217
Shortage status: resolved shortage (ended 2022-08-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02436906
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Clindamycin · DIN 02400529 · 150mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clindamycin · DIN 02400529 Manufacturer: Sanis Health Inc.; listing date 2022-04-29 Daily cost (source): $1.7736 Health Canada: Marketed since 2022-02-11 · brand CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 150 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Clindamycin: Formulary list price $0.2217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88532 · Verify on the e-Formulary ↗ (DIN 02400529)

Source record
DIN 02400529: Clindamycin Raw flags: sec3=Y Item: 081228006; group id 44; item number 0100; lccId None; manufacturer id SAI Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.2217; ministry $0.2217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02400529 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88532
Interchangeable products
Apo-Clindamycin · DIN 02245232 · $0.2217 Auro-Clindamycin · DIN 02436906 · $0.2217 Dalacin C · DIN 00030570 · not recorded Jamp-Clindamycin · DIN 02483734 · $0.2217 M-Clindamycin · DIN 02479923 · $0.2217 Med-Clindamycin · DIN 02462656 · $0.2217 NRA-Clindamycin · DIN 02493748 · $0.2217 Riva-Clindamycin · DIN 02468476 · $0.2217 Teva-Clindamycin · DIN 02241709 · $0.2217
Shortage status: resolved shortage (ended 2018-03-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02400529
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Clindamycin · DIN 02483734 · 150mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Clindamycin · DIN 02483734 Manufacturer: Jamp Pharma Corporation; listing date 2019-10-31 Daily cost (source): $1.7736 Health Canada: Marketed since 2019-09-27 · brand JAMP CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 150 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Clindamycin: Formulary list price $0.2217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97408 · Verify on the e-Formulary ↗ (DIN 02483734)

Source record
DIN 02483734: Jamp-Clindamycin Raw flags: sec3=Y Item: 081228006; group id 44; item number 0100; lccId None; manufacturer id JPC Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.2217; ministry $0.2217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02483734 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97408
Interchangeable products
Apo-Clindamycin · DIN 02245232 · $0.2217 Auro-Clindamycin · DIN 02436906 · $0.2217 Clindamycin · DIN 02400529 · $0.2217 Dalacin C · DIN 00030570 · not recorded M-Clindamycin · DIN 02479923 · $0.2217 Med-Clindamycin · DIN 02462656 · $0.2217 NRA-Clindamycin · DIN 02493748 · $0.2217 Riva-Clindamycin · DIN 02468476 · $0.2217 Teva-Clindamycin · DIN 02241709 · $0.2217
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02483734
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Clindamycin · DIN 02479923 · 150mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Clindamycin · DIN 02479923 Manufacturer: Mantra Pharma Inc.; listing date 2021-09-30 Daily cost (source): $1.7736 Health Canada: Marketed since 2019-05-28 · brand M-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 150 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Clindamycin: Formulary list price $0.2217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97049 · Verify on the e-Formulary ↗ (DIN 02479923)

Source record
DIN 02479923: M-Clindamycin Raw flags: sec3=Y Item: 081228006; group id 44; item number 0100; lccId None; manufacturer id MAT Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.2217; ministry $0.2217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479923 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97049
Interchangeable products
Apo-Clindamycin · DIN 02245232 · $0.2217 Auro-Clindamycin · DIN 02436906 · $0.2217 Clindamycin · DIN 02400529 · $0.2217 Dalacin C · DIN 00030570 · not recorded Jamp-Clindamycin · DIN 02483734 · $0.2217 Med-Clindamycin · DIN 02462656 · $0.2217 NRA-Clindamycin · DIN 02493748 · $0.2217 Riva-Clindamycin · DIN 02468476 · $0.2217 Teva-Clindamycin · DIN 02241709 · $0.2217
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02479923
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Med-Clindamycin · DIN 02462656 · 150mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Med-Clindamycin · DIN 02462656 Manufacturer: Generic Medical Partners Inc.; listing date 2022-04-29 Daily cost (source): $1.7736 Health Canada: Marketed since 2021-12-22 · brand MED-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 150 MG · company Generic medical partners inc · schedule Prescription
Check this DIN again · Health Canada product record

Med-Clindamycin: Formulary list price $0.2217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95045 · Verify on the e-Formulary ↗ (DIN 02462656)

Source record
DIN 02462656: Med-Clindamycin Raw flags: sec3=Y Item: 081228006; group id 44; item number 0100; lccId None; manufacturer id GMP Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.2217; ministry $0.2217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02462656 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95045
Interchangeable products
Apo-Clindamycin · DIN 02245232 · $0.2217 Auro-Clindamycin · DIN 02436906 · $0.2217 Clindamycin · DIN 02400529 · $0.2217 Dalacin C · DIN 00030570 · not recorded Jamp-Clindamycin · DIN 02483734 · $0.2217 M-Clindamycin · DIN 02479923 · $0.2217 NRA-Clindamycin · DIN 02493748 · $0.2217 Riva-Clindamycin · DIN 02468476 · $0.2217 Teva-Clindamycin · DIN 02241709 · $0.2217
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02462656
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Clindamycin · DIN 02493748 · 150mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
NRA-Clindamycin · DIN 02493748 Manufacturer: Nora Pharma; listing date 2020-10-30 Daily cost (source): $1.7736 Health Canada: Marketed since 2020-07-06 · brand NRA-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 150 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Clindamycin: Formulary list price $0.2217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98373 · Verify on the e-Formulary ↗ (DIN 02493748)

Source record
DIN 02493748: NRA-Clindamycin Raw flags: sec3=Y Item: 081228006; group id 44; item number 0100; lccId None; manufacturer id NRA Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.2217; ministry $0.2217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02493748 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98373
Interchangeable products
Apo-Clindamycin · DIN 02245232 · $0.2217 Auro-Clindamycin · DIN 02436906 · $0.2217 Clindamycin · DIN 02400529 · $0.2217 Dalacin C · DIN 00030570 · not recorded Jamp-Clindamycin · DIN 02483734 · $0.2217 M-Clindamycin · DIN 02479923 · $0.2217 Med-Clindamycin · DIN 02462656 · $0.2217 Riva-Clindamycin · DIN 02468476 · $0.2217 Teva-Clindamycin · DIN 02241709 · $0.2217
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02493748
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Clindamycin · DIN 02241709 · 150mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Clindamycin · DIN 02241709 Manufacturer: Teva Canada Limited; listing date 2000-11-30 Daily cost (source): $1.7736 Health Canada: Marketed since 2011-01-24 · brand TEVA-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 150 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Clindamycin: Formulary list price $0.2217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65371 · Verify on the e-Formulary ↗ (DIN 02241709)

Source record
DIN 02241709: Teva-Clindamycin Raw flags: sec3=Y Item: 081228006; group id 44; item number 0100; lccId None; manufacturer id TEV Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.2217; ministry $0.2217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241709 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65371
Interchangeable products
Apo-Clindamycin · DIN 02245232 · $0.2217 Auro-Clindamycin · DIN 02436906 · $0.2217 Clindamycin · DIN 02400529 · $0.2217 Dalacin C · DIN 00030570 · not recorded Jamp-Clindamycin · DIN 02483734 · $0.2217 M-Clindamycin · DIN 02479923 · $0.2217 Med-Clindamycin · DIN 02462656 · $0.2217 NRA-Clindamycin · DIN 02493748 · $0.2217 Riva-Clindamycin · DIN 02468476 · $0.2217
Shortage status: active shortage (reported 2025-10-08, last updated 2025-10-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241709
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Clindamycin · DIN 02436914 · 300mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Clindamycin · DIN 02436914 Manufacturer: Auro Pharma Inc.; listing date 2015-05-28 Health Canada: Marketed since 2015-03-02 · brand AURO-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 300 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Clindamycin: Formulary list price $0.4434/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4434 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92123 · Verify on the e-Formulary ↗ (DIN 02436914)

Source record
DIN 02436914: Auro-Clindamycin Raw flags: sec3=Y Item: 081228088; group id 44; item number 0101; lccId None; manufacturer id AUR Source form: Cap; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.4434; ministry $0.4434 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02436914 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92123
Interchangeable products
Apo-Clindamycin · DIN 02245233 · $0.4434 Clindamycin · DIN 02400537 · $0.4434 Dalacin C · DIN 02182866 · not recorded Jamp-Clindamycin · DIN 02483742 · $0.4434 M-Clindamycin · DIN 02479931 · $0.4434 Med-Clindamycin · DIN 02462664 · $0.4434 NRA-Clindamycin · DIN 02493756 · $0.4434 Riva-Clindamycin · DIN 02468484 · $0.4434 Teva-Clindamycin · DIN 02241710 · $0.4434
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02436914
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Clindamycin · DIN 02400537 · 300mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clindamycin · DIN 02400537 Manufacturer: Sanis Health Inc.; listing date 2022-04-29 Health Canada: Marketed since 2022-02-11 · brand CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 300 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Clindamycin: Formulary list price $0.4434/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4434 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88533 · Verify on the e-Formulary ↗ (DIN 02400537)

Source record
DIN 02400537: Clindamycin Raw flags: sec3=Y Item: 081228088; group id 44; item number 0101; lccId None; manufacturer id SAI Source form: Cap; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.4434; ministry $0.4434 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02400537 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88533
Interchangeable products
Apo-Clindamycin · DIN 02245233 · $0.4434 Auro-Clindamycin · DIN 02436914 · $0.4434 Dalacin C · DIN 02182866 · not recorded Jamp-Clindamycin · DIN 02483742 · $0.4434 M-Clindamycin · DIN 02479931 · $0.4434 Med-Clindamycin · DIN 02462664 · $0.4434 NRA-Clindamycin · DIN 02493756 · $0.4434 Riva-Clindamycin · DIN 02468484 · $0.4434 Teva-Clindamycin · DIN 02241710 · $0.4434
Shortage status: resolved shortage (ended 2018-03-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02400537
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Clindamycin · DIN 02483742 · 300mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Clindamycin · DIN 02483742 Manufacturer: Jamp Pharma Corporation; listing date 2019-10-31 Health Canada: Marketed since 2019-09-27 · brand JAMP CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 300 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Clindamycin: Formulary list price $0.4434/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4434 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97409 · Verify on the e-Formulary ↗ (DIN 02483742)

Source record
DIN 02483742: Jamp-Clindamycin Raw flags: sec3=Y Item: 081228088; group id 44; item number 0101; lccId None; manufacturer id JPC Source form: Cap; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.4434; ministry $0.4434 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02483742 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97409
Interchangeable products
Apo-Clindamycin · DIN 02245233 · $0.4434 Auro-Clindamycin · DIN 02436914 · $0.4434 Clindamycin · DIN 02400537 · $0.4434 Dalacin C · DIN 02182866 · not recorded M-Clindamycin · DIN 02479931 · $0.4434 Med-Clindamycin · DIN 02462664 · $0.4434 NRA-Clindamycin · DIN 02493756 · $0.4434 Riva-Clindamycin · DIN 02468484 · $0.4434 Teva-Clindamycin · DIN 02241710 · $0.4434
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02483742
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Clindamycin · DIN 02479931 · 300mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Clindamycin · DIN 02479931 Manufacturer: Mantra Pharma Inc.; listing date 2021-09-30 Health Canada: Marketed since 2019-05-28 · brand M-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 300 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Clindamycin: Formulary list price $0.4434/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4434 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97050 · Verify on the e-Formulary ↗ (DIN 02479931)

Source record
DIN 02479931: M-Clindamycin Raw flags: sec3=Y Item: 081228088; group id 44; item number 0101; lccId None; manufacturer id MAT Source form: Cap; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.4434; ministry $0.4434 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479931 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97050
Interchangeable products
Apo-Clindamycin · DIN 02245233 · $0.4434 Auro-Clindamycin · DIN 02436914 · $0.4434 Clindamycin · DIN 02400537 · $0.4434 Dalacin C · DIN 02182866 · not recorded Jamp-Clindamycin · DIN 02483742 · $0.4434 Med-Clindamycin · DIN 02462664 · $0.4434 NRA-Clindamycin · DIN 02493756 · $0.4434 Riva-Clindamycin · DIN 02468484 · $0.4434 Teva-Clindamycin · DIN 02241710 · $0.4434
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02479931
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Med-Clindamycin · DIN 02462664 · 300mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Med-Clindamycin · DIN 02462664 Manufacturer: Generic Medical Partners Inc.; listing date 2022-04-29 Health Canada: Marketed since 2021-12-22 · brand MED-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 300 MG · company Generic medical partners inc · schedule Prescription
Check this DIN again · Health Canada product record

Med-Clindamycin: Formulary list price $0.4434/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4434 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95046 · Verify on the e-Formulary ↗ (DIN 02462664)

Source record
DIN 02462664: Med-Clindamycin Raw flags: sec3=Y Item: 081228088; group id 44; item number 0101; lccId None; manufacturer id GMP Source form: Cap; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.4434; ministry $0.4434 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02462664 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95046
Interchangeable products
Apo-Clindamycin · DIN 02245233 · $0.4434 Auro-Clindamycin · DIN 02436914 · $0.4434 Clindamycin · DIN 02400537 · $0.4434 Dalacin C · DIN 02182866 · not recorded Jamp-Clindamycin · DIN 02483742 · $0.4434 M-Clindamycin · DIN 02479931 · $0.4434 NRA-Clindamycin · DIN 02493756 · $0.4434 Riva-Clindamycin · DIN 02468484 · $0.4434 Teva-Clindamycin · DIN 02241710 · $0.4434
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02462664
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Clindamycin · DIN 02493756 · 300mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
NRA-Clindamycin · DIN 02493756 Manufacturer: Nora Pharma; listing date 2020-10-30 Health Canada: Marketed since 2020-07-06 · brand NRA-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 300 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Clindamycin: Formulary list price $0.4434/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4434 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98374 · Verify on the e-Formulary ↗ (DIN 02493756)

Source record
DIN 02493756: NRA-Clindamycin Raw flags: sec3=Y Item: 081228088; group id 44; item number 0101; lccId None; manufacturer id NRA Source form: Cap; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.4434; ministry $0.4434 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02493756 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98374
Interchangeable products
Apo-Clindamycin · DIN 02245233 · $0.4434 Auro-Clindamycin · DIN 02436914 · $0.4434 Clindamycin · DIN 02400537 · $0.4434 Dalacin C · DIN 02182866 · not recorded Jamp-Clindamycin · DIN 02483742 · $0.4434 M-Clindamycin · DIN 02479931 · $0.4434 Med-Clindamycin · DIN 02462664 · $0.4434 Riva-Clindamycin · DIN 02468484 · $0.4434 Teva-Clindamycin · DIN 02241710 · $0.4434
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02493756
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Riva-Clindamycin · DIN 02468484 · 300mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Riva-Clindamycin · DIN 02468484 Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31 Health Canada: Marketed since 2017-10-13 · brand RIVA-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 300 MG · company Laboratoire riva inc. · schedule Prescription
Check this DIN again · Health Canada product record

Riva-Clindamycin: Formulary list price $0.4434/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4434 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95691 · Verify on the e-Formulary ↗ (DIN 02468484)

Source record
DIN 02468484: Riva-Clindamycin Raw flags: sec3=Y Item: 081228088; group id 44; item number 0101; lccId None; manufacturer id RIA Source form: Cap; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.4434; ministry $0.4434 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02468484 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95691
Interchangeable products
Apo-Clindamycin · DIN 02245233 · $0.4434 Auro-Clindamycin · DIN 02436914 · $0.4434 Clindamycin · DIN 02400537 · $0.4434 Dalacin C · DIN 02182866 · not recorded Jamp-Clindamycin · DIN 02483742 · $0.4434 M-Clindamycin · DIN 02479931 · $0.4434 Med-Clindamycin · DIN 02462664 · $0.4434 NRA-Clindamycin · DIN 02493756 · $0.4434 Teva-Clindamycin · DIN 02241710 · $0.4434
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468484
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Clindamycin · DIN 02241710 · 300mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Clindamycin · DIN 02241710 Manufacturer: Teva Canada Limited; listing date 2000-11-30 Health Canada: Marketed since 2011-01-24 · brand TEVA-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 300 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Clindamycin: Formulary list price $0.4434/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4434 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65372 · Verify on the e-Formulary ↗ (DIN 02241710)

Source record
DIN 02241710: Teva-Clindamycin Raw flags: sec3=Y Item: 081228088; group id 44; item number 0101; lccId None; manufacturer id TEV Source form: Cap; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.4434; ministry $0.4434 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241710 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65372
Interchangeable products
Apo-Clindamycin · DIN 02245233 · $0.4434 Auro-Clindamycin · DIN 02436914 · $0.4434 Clindamycin · DIN 02400537 · $0.4434 Dalacin C · DIN 02182866 · not recorded Jamp-Clindamycin · DIN 02483742 · $0.4434 M-Clindamycin · DIN 02479931 · $0.4434 Med-Clindamycin · DIN 02462664 · $0.4434 NRA-Clindamycin · DIN 02493756 · $0.4434 Riva-Clindamycin · DIN 02468484 · $0.4434
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241710
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Riva-Clindamycin · DIN 02468476 · 150mg · capsule

General benefitDormant since 2025-07-22 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Riva-Clindamycin · DIN 02468476 Manufacturer: Laboratoire Riva Inc.; listing date 2021-09-30 Daily cost (source): $1.7736 Health Canada: Dormant since 2025-07-22 · brand RIVA-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 150 MG · company Laboratoire riva inc. · schedule Prescription
Check this DIN again · Health Canada product record

Riva-Clindamycin: Formulary list price $0.2217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95690 · Verify on the e-Formulary ↗ (DIN 02468476)

Source record
DIN 02468476: Riva-Clindamycin Raw flags: sec3=Y Item: 081228006; group id 44; item number 0100; lccId None; manufacturer id RIA Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.2217; ministry $0.2217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02468476 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95690
Interchangeable products
Apo-Clindamycin · DIN 02245232 · $0.2217 Auro-Clindamycin · DIN 02436906 · $0.2217 Clindamycin · DIN 02400529 · $0.2217 Dalacin C · DIN 00030570 · not recorded Jamp-Clindamycin · DIN 02483734 · $0.2217 M-Clindamycin · DIN 02479923 · $0.2217 Med-Clindamycin · DIN 02462656 · $0.2217 NRA-Clindamycin · DIN 02493748 · $0.2217 Teva-Clindamycin · DIN 02241709 · $0.2217
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468476
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-22 — choose a marketed DIN from the same-category list.

Apo-Clindamycin · DIN 02245232 · 150mg · capsule

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued 2025-04-17 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Clindamycin · DIN 02245232 Manufacturer: Apotex Inc.; listing date 2002-07-29 Daily cost (source): $1.7736 Health Canada: Cancelled post market since 2025-04-17 · brand APO-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 150 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Clindamycin: Formulary list price $0.2217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69247 · Verify on the e-Formulary ↗ (DIN 02245232)

Source record
DIN 02245232: Apo-Clindamycin Raw flags: sec3=Y Item: 081228006; group id 44; item number 0100; lccId None; manufacturer id APX Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.2217; ministry $0.2217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245232 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69247
Interchangeable products
Auro-Clindamycin · DIN 02436906 · $0.2217 Clindamycin · DIN 02400529 · $0.2217 Dalacin C · DIN 00030570 · not recorded Jamp-Clindamycin · DIN 02483734 · $0.2217 M-Clindamycin · DIN 02479923 · $0.2217 Med-Clindamycin · DIN 02462656 · $0.2217 NRA-Clindamycin · DIN 02493748 · $0.2217 Riva-Clindamycin · DIN 02468476 · $0.2217 Teva-Clindamycin · DIN 02241709 · $0.2217
Shortage status: discontinued (2019-05-21, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245232
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.

Apo-Clindamycin · DIN 02245233 · 300mg · capsule

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued 2025-04-17 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Clindamycin · DIN 02245233 Manufacturer: Apotex Inc.; listing date 2002-07-29 Health Canada: Cancelled post market since 2025-04-17 · brand APO-CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 300 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Clindamycin: Formulary list price $0.4434/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4434 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69248 · Verify on the e-Formulary ↗ (DIN 02245233)

Source record
DIN 02245233: Apo-Clindamycin Raw flags: sec3=Y Item: 081228088; group id 44; item number 0101; lccId None; manufacturer id APX Source form: Cap; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.4434; ministry $0.4434 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245233 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69248
Interchangeable products
Auro-Clindamycin · DIN 02436914 · $0.4434 Clindamycin · DIN 02400537 · $0.4434 Dalacin C · DIN 02182866 · not recorded Jamp-Clindamycin · DIN 02483742 · $0.4434 M-Clindamycin · DIN 02479931 · $0.4434 Med-Clindamycin · DIN 02462664 · $0.4434 NRA-Clindamycin · DIN 02493756 · $0.4434 Riva-Clindamycin · DIN 02468484 · $0.4434 Teva-Clindamycin · DIN 02241710 · $0.4434
Shortage status: discontinued (2019-07-12, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245233
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.

Dalacin C · DIN 00030570 · 150mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.Discontinued 2024-10-24 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dalacin C · DIN 00030570 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Daily cost (source): $1.7736 Health Canada: Cancelled post market since 2024-10-24 · brand DALACIN C 150 MG · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 150 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Dalacin C: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=874 · Verify on the e-Formulary ↗ (DIN 00030570)

Source record
DIN 00030570: Dalacin C Raw flags: notABenefit=Y, sec3=Y Item: 081228006; group id 44; item number 0100; lccId None; manufacturer id PFI Source form: Cap; strength: 150mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00030570 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=874
Interchangeable products
Apo-Clindamycin · DIN 02245232 · $0.2217 Auro-Clindamycin · DIN 02436906 · $0.2217 Clindamycin · DIN 02400529 · $0.2217 Jamp-Clindamycin · DIN 02483734 · $0.2217 M-Clindamycin · DIN 02479923 · $0.2217 Med-Clindamycin · DIN 02462656 · $0.2217 NRA-Clindamycin · DIN 02493748 · $0.2217 Riva-Clindamycin · DIN 02468476 · $0.2217 Teva-Clindamycin · DIN 02241709 · $0.2217
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00030570
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.

Dalacin C · DIN 02182866 · 300mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.Discontinued 2024-10-24 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dalacin C · DIN 02182866 Manufacturer: Pfizer Canada Inc.; listing date 1996-12-19 Health Canada: Cancelled post market since 2024-10-24 · brand DALACIN C 300 MG · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 300 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Dalacin C: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19455 · Verify on the e-Formulary ↗ (DIN 02182866)

Source record
DIN 02182866: Dalacin C Raw flags: notABenefit=Y, sec3=Y Item: 081228088; group id 44; item number 0101; lccId None; manufacturer id PFI Source form: Cap; strength: 300mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02182866 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19455
Interchangeable products
Apo-Clindamycin · DIN 02245233 · $0.4434 Auro-Clindamycin · DIN 02436914 · $0.4434 Clindamycin · DIN 02400537 · $0.4434 Jamp-Clindamycin · DIN 02483742 · $0.4434 M-Clindamycin · DIN 02479931 · $0.4434 Med-Clindamycin · DIN 02462664 · $0.4434 NRA-Clindamycin · DIN 02493756 · $0.4434 Riva-Clindamycin · DIN 02468484 · $0.4434 Teva-Clindamycin · DIN 02241710 · $0.4434
Shortage status: discontinued (2024-10-29, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02182866
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.

CLINDAMYCIN PHOSPHATE

1 general benefit · 1 not a benefit

Other products in the same Health Canada class (D10AF) — coverage varies; not interchangeable

  • Benzoyl peroxide + clindamycin (Clindoxyl): general benefit
  • Adapalene + benzoyl peroxide + clindamycin (Cabtreo): limited Use 724

Clindamycin Phosphate Injection USP · DIN 02230540 · 300mg/2mL · injection solution-2mL Pk

Listed, not a benefitMarketed · checked 2026-09-02
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clindamycin Phosphate Injection USP · DIN 02230540 Manufacturer: Sandoz Canada Inc.; listing date 2001-03-07 Health Canada: Marketed since 2005-08-26 · brand CLINDAMYCIN INJECTION USP · ATC J01FF01 CLINDAMYCIN · form Liquid · route Intravenous, Intramuscular · ingredients CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 150 MG/ML · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Clindamycin Phosphate Injection USP: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49612 · Verify on the e-Formulary ↗ (DIN 02230540)

Source record
DIN 02230540: Clindamycin Phosphate Injection USP Raw flags: notABenefit=Y, sec3=Y Item: 081228008; group id 46; item number 0103; lccId None; manufacturer id SDZ Source form: Inj Sol-2mL Pk; strength: 300mg/2mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230540 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49612 Therapeutic Notes (formulary) Clindamycin is well absorbed by the oral route, therefore stepdown therapy from IV to oral is possible.
Interchangeable products
Dalacin C · DIN 00260436 · $8.8938
Shortage status: resolved shortage (ended 2023-08-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230540
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Dalacin C · DIN 00260436 · 300mg/2mL · injection solution-2mL Pk

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-06-30 — choose a marketed DIN from the same-category list.Discontinued 2026-06-30 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-06-30 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-06-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dalacin C · DIN 00260436 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2026-06-30 · brand DALACIN C PHOSPHATE · ATC J01FF01 CLINDAMYCIN · form Solution · route Intramuscular, Intravenous · ingredients CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 150 MG/ML · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Dalacin C: Formulary list price $8.8938/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.8938 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1620 · Verify on the e-Formulary ↗ (DIN 00260436)

Source record
DIN 00260436: Dalacin C Raw flags: sec3=Y Item: 081228008; group id 46; item number 0103; lccId None; manufacturer id PFI Source form: Inj Sol-2mL Pk; strength: 300mg/2mL Recorded listing: General benefit Source prices (unrounded): $8.8938; ministry $8.8938 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00260436 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1620 Therapeutic Notes (formulary) Clindamycin is well absorbed by the oral route, therefore stepdown therapy from IV to oral is possible.
Interchangeable products
Clindamycin Phosphate Injection USP · DIN 02230540 · not recorded
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00260436
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-06-30 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free)

RIFAXIMIN

· 1 products · Limited Use, codes 475 · strengths: 550mg · Tab

VANCOMYCIN HCL

· 4 products · Limited Use, codes 557, 558, 559, 560 (2), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 125mg, 250mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:28 and 3 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles

Other drugs in the same formulary class (84:04:04 Antibiotics) and how they are covered

Matched class: 84:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE, FUSIDIC ACID, MUPIROCIN CALCIUM, SODIUM FUSIDATE Some products covered without a code (check the product listing): MUPIROCIN 84:04:04 Antibiotics

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

· 4 products · General benefit · strengths: 1% & 5% · Gel, Top Gel

CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE

· 1 products · Limited Use, codes 724 · strengths: 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Oint

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:04
Full class listing Related classes: 84:04:08 Fungicides, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: acne, bacterial endocarditis, bone and joint infections, gynecological infections, intra-abdominal infections, septicemia, skin and skin structure infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CLINDAMYCIN PALMITATE CEFOXITIN SODIUM · Off-Formulary Interchangeable, not an ODB benefit 1 - Intra-abdominal infections such as peritonitis and intra-abdominal abscess PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 2 - Gynecological infections such as endometritis and pelvic cellulitis PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 3 - Septicemia PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 6 - Bone and joint infections caused by Staphylococcus aureus PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph CEFTRIAXONE DISODIUM · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) • Skin and Skin Structure Infections caused by K. pneumoniae and species, P. mirabilis, Staph. aureus, Staph. epidermidis and Streptococcus species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph • Bone and Joint Infections caused by Staph. aureus, Strep. pneumoniae and Streptococcus species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph • Intra-Abdominal Infections caused by E.coli and K. pneumoniae. PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph CEFADROXIL · Listed, not a benefit (1), General benefit (3) • Skin and skin structure infections caused by Staphylococcus aureus and/or Group A ß– hemolytic streptococci. PM: https://pdf.hres.ca/dpd_pm/00056563.PDF; date May 20, 2020; DIN 02235134; fetched 2026-09-10 Product monograph CLINDAMYCIN PALMITATE · General benefit DALACIN C FLAVOURED GRANULES is indicated for prophylaxis against alpha-hemolytic (viridans group) streptococci before dental, oral and upper respiratory tract surgery. a) The prophylaxis of bacterial endocarditis in patients allergic to penicillin with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular dysfunction, prosthetic heart valves, previous history of bacterial endocarditis, hypertrophic cardiomyopathy, surgically constructed systemic-pulmonary shunts, mitral valve prolapse with valvular regurgitation or mitral valve prolapse without regurgitation but associated with thickening and/or redundancy of the valve leaflets. b) Patients taking oral penicillin for prevention or recurrence of rheumatic fever should be given another agent such as clindamycin, for prevention of bacterial endocarditis. PM: https://pdf.hres.ca/dpd_pm/00085121.PDF; date 2026-06-23; DIN 00225851; fetched 2026-09-10 Product monograph CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE · Limited Use, codes 724 1 INDICATIONS CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. PM: https://pdf.hres.ca/dpd_pm/00076715.PDF; date AUG 14, 2024; DIN 02550423; fetched 2026-09-10 Product monograph TAZAROTENE · Limited Use, codes 636 1 INDICATIONS ARAZLO™ (tazarotene lotion), is indicated for: • For the topical treatment of acne vulgaris in patients 10 years of age and older. 1.1 Pediatrics Pediatrics (≥ 10 years of age) The safety and efficacy of ARAZLO in pediatric patients (10 years of age and older) has been established. PM: https://pdf.hres.ca/dpd_pm/00082613.PDF; date NOV 28, 2025; DIN 02517868; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Taro-Clindamycin 1% (clindamycin phosphate) is indicated for the treatment of acne vulgaris. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALACIN T and other antibacterial drugs, DALACIN T should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Geriatrics (> 65 years of age): Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients. Pediatrics Safety and effectiveness in pediatric patients under the age of 12 have not been established. https://pdf.hres.ca/dpd_pm/00058691.PDF PM date: not printed or not captured Source product: TARO-CLINDAMYCIN; DIN 02266938; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS TEVA-CLINDAMYCIN (clindamycin hydrochloride capsules) is indicated in the treatment of serious infections due to sensitive anaerobic bacteria, such as Bacteroides species, Peptostreptococcus, anaerobic streptococci, Clostridium species and microaerophilic streptococci. TEVA-CLINDAMYCIN is also indicated in serious infections due to sensitive gram-positive aerobic organisms (staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci) when the patient is intolerant of, or the organism is resistant to other appropriate antibiotics. TEVA-CLINDAMYCIN is indicated for the treatment of the Pneumocystis jiroveci pneumonia in patients with AIDS. Clindamycin in combination with primaquine may be used in patients who are intolerant to, or fail to respond to conventional therapy. TEVA-CLINDAMYCIN is indicated for prophylaxis against alpha-hemolytic (viridans group) streptococci before dental, oral and upper respiratory tract surgery. a) The prophylaxis of bacterial endocarditis in patients allergic to penicillin with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular dysfunction… https://pdf.hres.ca/dpd_pm/00077874.PDF PM date: February 16, 2000 Source product: TEVA-CLINDAMYCIN; DIN 02241709; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications Clindamycin Injection USP (clindamycin phosphate) is indicated for the treatment of serious infections due to susceptible anaerobic bacteria, such as Bacteroides species, Peptostreptococcus, anaerobic streptococci, Clostridium species and microaerophilic streptococci. Clindamycin Injection USP is also indicated for the treatment of serious infections due to susceptible strains of gram positive aerobic bacteria (staphylococci, including penicillinase- producing staphylococci, streptococci and pneumococci) as well as in the treatment of Chlamydia trachomatis, when the patient is intolerant of, or the organism is resistant to other appropriate antibiotics. Because of the risk of Clostridium difficile-associated disease (CDAD) as described in 7 Warnings and Precautions, before selecting clindamycin the healthcare professional should consider the nature of the infection and the suitability of alternative therapy. Clindamycin Injection USP is indicated for the treatment of the following serious infections when caused by susceptible strains of the designated organisms in the conditions listed below: • Lower respiratory infections including pneumonia, empyema… https://pdf.hres.ca/dpd_pm/00085906.PDF PM date: AUG 27, 2026 Source product: CLINDAMYCIN INJECTION USP; DIN 02230540; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Taro-Clindamycin · DIN 02266938 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02266938

Check this DIN again

Dalacin T 1% · DIN 00582301 Shortage status: active shortage (reported 2018-01-26, last updated 2019-03-11) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00582301

Check this DIN again

Teva-Clindamycin · DIN 02241709 Shortage status: active shortage (reported 2025-10-08, last updated 2025-10-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241709

Check this DIN again

Teva-Clindamycin · DIN 02241710 Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241710

Check this DIN again

Apo-Clindamycin · DIN 02245232 Shortage status: discontinued (2019-05-21, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245232

Check this DIN again

Apo-Clindamycin · DIN 02245233 Shortage status: discontinued (2019-07-12, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245233

Check this DIN again

Dalacin C · DIN 02182866 Shortage status: discontinued (2024-10-29, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02182866

Check this DIN again

Dalacin C · DIN 00260436 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00260436

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Taro-Clindamycin, Dalacin T 1%, Dalacin C, Clindamycin Phosphate Injection USP: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026